Question 1

What is combined oxidative phosphorylation defect type 2?

Accepted Answer

Combined oxidative phosphorylation defect type 2 is a severe mitochondrial disorder that affects multiple systems from the earliest stages of development. The condition arises due to pathogenic variants in the MRPS16 gene, which impairs mitochondrial protein synthesis and energy production. Typically, affected individuals present in the prenatal or immediate postnatal period with features such as intrauterine growth restriction and significant neonatal abnormalities. It is an exceptionally rare condition, affecting fewer than 1 in one million people.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 2?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation defect type 2 is marked by a number of consistent and severe features noted at or before birth. Characteristically, there is evidence of significant fetal compromise, with documented small size for gestational age, mild ventriculomegaly, and generalized edema. At birth, neonates present with limb edema, redundant skin on the neck, and low-set ears, alongside critical systemic derangements such as severe lactic acidosis and elevated hepatic transaminases. Neurologically, affected infants exhibit profound hypotonia, lethargy, and an almost complete absence of spontaneous movements. Additional consistent findings include brachydactyly and structural brain abnormalities like agenesis of the corpus callosum. Not all individuals experience every feature, and severity can vary, though the overall clinical picture is uniformly devastating as described in the available evidence.

Question 3

What causes combined oxidative phosphorylation defect type 2?

Accepted Answer

This condition is caused by pathogenic variants in the MRPS16 gene, which plays a critical role in the mitochondrial protein synthesis machinery required for energy production in cells. The defective protein synthesis impairs the function of several mitochondrial respiratory complexes, leading to decreased enzyme activity in the muscle and liver. Inheritance follows an autosomal recessive pattern, meaning that an affected individual inherits one mutated copy of MRPS16 from each parent. That this condition is more common when parents share a common ancestor; in such families, both parents are more likely to carry the same rare genetic variant. Genetic counseling is recommended for families to understand the implications and recurrence risks associated with autosomal recessive inheritance. Associated genes include MRPS16.

Question 4

How is combined oxidative phosphorylation defect type 2 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 2 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 2?

Accepted Answer

combined oxidative phosphorylation defect type 2 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 2 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation defect type 2 relies on a combination of clinical evaluation and molecular genetic testing. The hallmark clinical findings, including intrauterine growth retardation, edema, and severe metabolic disturbances such as lactic acidosis, prompt further investigation. The definitive diagnosis is achieved by identifying pathogenic variants in the MRPS16 gene through molecular genetic testing. Although specific diagnostic methods are not detailed in the available data, laboratory investigations may also reveal markedly decreased activities of mitochondrial complexes in muscle and liver tissues, supporting the clinical suspicion. Given the overlap of these features with other conditions, genetic testing is essential to confirm the diagnosis and differentiate it from other metabolic or mitochondrial disorders.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 2?

Accepted Answer

Currently, there are no FDA-approved or foundational therapies specifically targeting combined oxidative phosphorylation defect type 2. Management focuses on supportive care aimed at alleviating symptoms and minimizing complications where possible. Given the multisystem involvement, treatment typically involves a multidisciplinary team that includes metabolic specialists, neonatologists, and other healthcare professionals experienced in managing complex mitochondrial disorders. Long-term management involves regular surveillance and monitoring to identify emerging complications early, and supportive interventions such as nutritional support and careful management of metabolic crises are essential. Families are encouraged to discuss all possible treatment options with their healthcare team, including the role of genetic counseling in understanding the condition and family planning.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 2?

Accepted Answer

Combined oxidative phosphorylation defect type 2 can lead to severe complications, especially in the neonatal period. Infants may experience profound metabolic instability and issues with multiple organ systems, which can result in life-threatening situations. Regular monitoring and supportive care are crucial to manage these complications.

Question 9

How does combined oxidative phosphorylation defect type 2 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 2 can be challenging for both patients and their families. Daily life may involve frequent medical appointments, monitoring for metabolic crises, and managing symptoms. Families often need to work closely with a team of healthcare professionals to provide the best supportive care.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 2?

Accepted Answer

The prognosis for combined oxidative phosphorylation defect type 2 is generally poor, with many infants facing severe complications shortly after birth. While some outcomes may vary based on individual circumstances and timely interventions, the overall outlook remains grim. Families are encouraged to seek support and guidance from specialists experienced in this condition.

Question 11

What should families consider regarding genetic counseling for combined oxidative phosphorylation defect type 2?

Accepted Answer

Genetic counseling is important for families affected by combined oxidative phosphorylation defect type 2. It helps them understand the autosomal recessive inheritance pattern and the risks of recurrence in future pregnancies. A genetic counselor can provide valuable information and support for family planning decisions.

Research Type	Count	% of Total
Laboratory research	59	58%

Kisho

combined oxidative phosphorylation defect type 2

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation defect type 2

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 2?

What are the symptoms of combined oxidative phosphorylation defect type 2?

What causes combined oxidative phosphorylation defect type 2?

How is combined oxidative phosphorylation defect type 2 inherited?

How rare is combined oxidative phosphorylation defect type 2?

How is combined oxidative phosphorylation defect type 2 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 2?

What complications can arise from combined oxidative phosphorylation defect type 2?

How does combined oxidative phosphorylation defect type 2 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 2?

What should families consider regarding genetic counseling for combined oxidative phosphorylation defect type 2?

Explore clinical features

Recent Publications